胶质瘤中的分子标志物
本文是一篇综述,面向临床与基础研究者,总结胶质瘤中较知名的分子标志物(MGMT、1p/19q、IDH、EGFR、p53、PI3K、Rb、RAF),讨论其识别方法及可能的临床相关性,并介绍研究 putative 胶质瘤干细胞(GSC)的识别方法(CD133、CD15、A2B5、nestin、ALDH1、蛋白酶体活性、ABC 转运蛋白、标记保留)。
要点
- 综述总结 MGMT、1p/19q、IDH、EGFR、p53、PI3K、Rb、RAF 等胶质瘤分子标志物及其识别方法与临床相关性。
- 介绍研究 putative GSC 的识别方法,包括 CD133、CD15、A2B5、nestin、ALDH1、蛋白酶体活性、ABC 转运蛋白和标记保留。
- 作者指出仍有许多未明之处,可能解释文献中的部分矛盾报道;单一标志物不太可能前瞻性识别和分离所有或任一胶质瘤的 GSC。
核心结论
- 尽管对这些标志物已有大量研究,但仍有大量未知,可能解释文献中的部分矛盾报道。
- 研究者不太可能利用单一标志物前瞻性识别和分离所有或任一胶质瘤的 GSC。
研究设计与样本
- 本文为综述,定位为临床与基础研究者的实用资源,总结胶质瘤中较知名的分子标志物并讨论其识别方法与临床相关性。
主要发现
- 综述总结了 MGMT、1p/19q、IDH、EGFR、p53、PI3K、Rb 和 RAF 等分子标志物。
- 综述讨论了这些标志物的识别方法及其可能具有的临床相关性,并讨论了这些标志物的一些特定生物学。
- 综述介绍了研究 putative GSC 的识别方法,包括 CD133、CD15、A2B5、nestin、ALDH1、蛋白酶体活性、ABC 转运蛋白和标记保留。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出仍有许多未明之处,可能解释文献中的部分矛盾报道。
- 作者指出研究者不太可能利用单一标志物前瞻性识别和分离所有或任一胶质瘤的 GSC。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gliomas are the most malignant and aggressive form of brain tumors, and account for the majority of brain cancer related deaths. Malignant gliomas, including glioblastoma are treated with radiation and temozolomide, with only a minor benefit in survival time. A number of advances have been made in understanding glioma biology, including the discovery of cancer stem cells, termed glioma stem cells (GSC). Some of these advances include the delineation of molecular heterogeneity both between tumors from different patients as well as within tumors from the same patient. Such research highlights the importance of identifying and validating molecular markers in glioma. This review, intended as a practical resource for both clinical and basic investigators, summarizes some of the more well-known molecular markers (MGMT, 1p/19q, IDH, EGFR, p53, PI3K, Rb, and RAF), discusses how they are identified, and what, if any, clinical relevance they may have, in addition to discussing some of the specific biology for these markers. Additionally, we discuss identification methods for studying putative GSC's (CD133, CD15, A2B5, nestin, ALDH1, proteasome activity, ABC transporters, and label-retention). While much research has been done on these markers, there is still a significant amount that we do not yet understand, which may account for some conflicting reports in the literature. Furthermore, it is unlikely that the investigator will be able to utilize one single marker to prospectively identify and isolate GSC from all, or possibly, any gliomas.
引用
- Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol. 2017. PMID: 28233083. doi:10.1007/s11060-017-2379-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。